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Summary 
Bovine papillomavirus (BPV) induces papillomas, which in the great majority of cases 
regress due to the host immune response, but can persist and progress to malignancy. Even 
in the absence of malignant transformation, BPV infection persists for a significant period of 
time before activation of the host immune system, suggesting that the host immune system is 
unaware of, or disabled by, BPV. E5 is the major oncoprotein of BPV, which, in addition to 
its transforming properties, down-regulates the expression and the transport to the cell 
surface of major histocompatibility complex class I (MHC I). Here we show that co-
expression of MHC I and E5 in papillomas caused by BPV-4 infection is mutually 
exclusive, in agreement with the inhibition of surface MHC I expression by E5 observed in 
vitro. The inhibition of MHC expression in E5-expressing papilloma cells could explain the 
long period required for the activation of the immune response and has implications for the 
progression of papillomas to the malignant stage: absence of peptide presentation by MHC I 
to cytotoxic T lymphocytes  (CTL) would allow the infected cells to evade the host cellular 
immune response and the lesions to persist.  
 
Text 
Papillomaviruses are oncogenic viruses which induce benign proliferative lesions of 
epithelia, called papillomas or warts. Papillomavirus infections are usually eliminated by a 
cell-mediated immune response directed against viral antigens (O'Brien & Campo, 2002). 
However, in a minority of cases mucosal lesions do not regress and can progress to cancer. 
High risk human papillomavirus types 16 and 18 (HPV-16 and -18) are the main causative 
factor in the development of cancer of the cervix uteri (zur Hausen, 2002). Bovine 
papillomavirus types 1 and 2 (BPV-1 and -2) and BPV-4 are involved in carcinogenesis of 
the urinary bladder and the alimentary tract in cattle, respectively; BPV-1 is also involved 
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in cancer of the penis (Campo, 1997, Campo, 2002). In all cases, cancer is preceded by, 
and derives from, pre-existing papillomas.  
Papillomas induced by BPV develop through four well defined stages, from stage 1 or 
plaque, the first clinical manifestation of infection, to stage 4 when the papilloma starts 
regressing (Jarrett, 1985). From infection to regression, papilloma development takes often 
more than twelve months. In the case of BPV-4-induced papillomas, regression is 
accompanied by infiltration of immune cells, primarily CD4+ T lymphocytes in the 
adjacent dermis, as well as CD8+ T lymphocytes infiltrating the keratinocytes (Knowles et 
al., 1996). Persistence, spread and progression of papillomas to cancer occurs mainly in 
animals grazing on bracken fern (Pteridium spp) (Campo et al., 1994). These animals are 
immunocompromised by immunosuppressants, such as sesquiterpenes, present in the plant. 
However, papillomas can also spread and persist in cattle not exposed to bracken fern 
(Tsirimonaki et al., 2003). Even in the absence of malignant transformation, BPV infection 
can persist for a significant period of time before activation of the host immune system. 
Lymphocytes from infected animals do not recognise early or late viral antigens until late 
in infection, despite the presence of numerous papillomas actively producing virus 
(Chandrachud et al., 1994, Chandrachud et al., 1995, Kirnbauer et al., 1996, McGarvie et 
al., 1995). This lack of recognition suggests that the host immune system is unaware of, or 
disabled by, BPV infection. It is now known that papillomaviruses can subvert the immune 
response indirectly, since viral replication is confined to the epithelial cells above the basal 
membrane and therefore in a site recognised poorly by immune cells (Frazer et al., 1999). 
In addition, papillomaviruses appear to interfere directly with host anti-viral immune 
mechanisms, including the interferon response and major histocompatibility complex class 
I (MHC I) antigen presentation to cytotoxic T lymphocytes (CTLs)  (O'Brien & Campo, 
2002, Tindle, 2002) . 
 4
We have recently shown that expression of the E5 oncoprotein of BPV-1, BPV-4 and 
HPV-16 has a profound effect on the synthesis and transport of MHC I in cultured cells 
and therefore can potentially contribute to the ability of the virus to evade immune-
recognition (Ashrafi et al., 2004, Ashrafi et al., 2002, Marchetti et al., 2002, O'Brien & 
Campo, 2002). To ascertain whether the down-regulation of MHC I observed in cultured 
cells takes place in tumours, we investigated the expression of BPV-4 E5 and MHC I in 
clinical samples of BPV-4 papillomas.  
Papillomas from the palate, rumen and oesophagus, as well as samples of normal palate, 
tongue and buccal mucosa, were collected post mortem from animals referred to the 
University of Glasgow Veterinary School. Tissue samples were fixed and stored in 10% 
formaldehyde in phosphate-buffered saline (PBS) at pH 7.5 and then embedded in paraffin 
wax for histological processing. Serial sections (1.5 μm) were cut and placed on 
microscopic slides treated with VECTABOND (Vector, USA). After de-paraffinisation in 
Histo-clear (National Diagnostics, USA), the sections were re-hydrated in graded ethanol 
and incubated in 0.5% H2O2/methanol for 20 minutes to quench endogenous peroxidase. 
Sections were subjected to antigen retrieval treatment with 0.01M sodium citrate buffer 
(pH 6) in a pressure cooker for 75 seconds at 103.4 kPa, blocked with 1% normal 
unlabelled swine serum (Scottish Antibody Production Unit, UK) in TBS containing 0.1% 
Tween 20 for 30 minutes at room temperature and then incubated for 1.5 hours at room 
temperature with primary antibodies for detection of E5, E7, MHC I heavy chain and the 
proliferation marker Ki67 as detailed below. The sections were then incubated with biotin-
labelled secondary antibody (Dako, UK) and streptavidin-biotin complex (Dako) for 45 
minutes as per the manufacturer’s instructions. Immunoreactivity was visualised with 3,3 
diaminobenzidine (DAB, Sigma, UK). Sections were counterstained with Gills 
haematoxylin, dehydrated, cleared in Histo-clear and then permanently mounted with DPX 
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mountant and cover-slipped prior to microscopic examination. A total of seven papillomas 
were analysed, with at least three sections and three different section fields examined per 
papilloma; all papillomas were classified as stage 2/3, i.e. mature papillomas producing 
virus, and presented the typical features of BPV-4 infection (Jarrett, 1985), including an 
irregular basal layer (Figure 1A, B), fronds of transformed cells terminating in keratinised 
tips (Figure 2D), and koilocytes, cells with highly enlarged cytoplasm typical of 
papillomavirus infection (Figure 2D, black arrow). In contrast, the normal bovine 
alimentary mucosal epithelium had a typical architecture composed of a regular basal cell 
layer, suprabasal, spinous, and squamous layers (Figure 1D). 
BPV-4 E5 was detected with each of two rabbit antisera, 274 and 275, raised against a 
synthetic peptide representing the 12 C-terminal amino acids of the protein, conjugated to 
keyhole limpet hemocyanin (KLH) (Anderson et al., 1997). Similar results were obtained 
with both anti-E5 antisera; only results obtained with antiserum 274 are shown. In 
agreement with previous results of ourselves and others (Burnett et al., 1992; Anderson et 
al., 1997), E5 was detected exclusively in the cytoplasm of epidermal cells, from the basal 
and parabasal layers to the spinous and squamous layers (Figures 1A,B, 2D). Expression 
was, however, discontinuous, as already reported (Anderson et al., 1997); no papilloma 
was stained in all the cell layers. To verify the specificity of the immunostaining of E5, 
several controls were carried out. There was no staining with pre-immune serum (data not 
shown) or when only the secondary antibody was used (Figure 1C) and the E5 antiserum 
did not react with normal mucosa (Figure 1D). Further, the E5 antiserum was pre-absorbed 
with the antigen peptide (3 μg peptide/ml antiserum). Pre-absorption eliminated reactivity 
both in immunoprecipitation of in vitro translated E5 labelled with S35 methionine (Figure 
1E), and immunostaining experiments (Figure 1F). E5 expression in the differentiated 
layers of the papillomas was often accompanied by expression of the proliferation antigen 
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Ki67 (Figure 3G), detected by monoclonal antibody MIB-1 (Dako). Expression of Ki67 
confirmed the transformed nature of these cells: in normal epithelia cells cease to 
proliferate once they leave the basal layer.  
To analyse expression of MHC I in papillomas we incubated sample sections with mAb 
IL-A88, which detects the heavy chain of bovine MHC I (Toye et al., 1990). In normal 
epithelium, there was strong staining of the capillaries and of stromal cells; the epithelium 
was stained throughout most of its thickness (Figure 2A) and staining on the surface of the 
cells was particularly clear in cells of the basal and suprabasal layers (Figure 2B). There 
was no staining without primary antibody (data not shown). In sections of papillomas, 
MHC I could be detected in stroma and capillaries (Figure 3E), and on the surface of some 
epithelial cells, as in normal tissue, but not in cells expressing E5 (Figures 2D,E; 3A,B), 
independently of whether the cells were in the deeper layers (Figure 3A,B) the suprabasal 
transit and lower spinous layers (Figure 2D,E, boxed area 1), or the more superficial layers 
(Figure 2D,E; 3D,E). These results suggest that expression of E5 is incompatible with the 
expression of MHC I. 
The E7 protein of HPV-16 and HPV-11 has been implicated, respectively, in the down-
regulation of MHC I, either through inhibition of the transcriptional promoter of the MHC 
I heavy chain (Georgopoulos et al., 2000), or indirectly through inhibition of TAP, the 
transporter associated with peptide (Vambutas et al., 2001). To ensure that the absence of 
MHC I in bovine papillomas was due to E5 and not to E7, we stained papilloma sections 
with rabbit antisera 11547 and 11823 raised against a β-gal-E7 fusion protein (Anderson et 
al., 1997). Similar results were obtained with both antisera; only results with antiserum 
11547 are shown. E5 and E7 are co-expressed in the same cells (Anderson et al., 1997), 
and, accordingly, in this study cells that expressed either E5 or E7 alone were seldom 
detected. Nevertheless, in cells that expressed E5 and did not express E7, or expressed it at 
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levels below detection, there was little or no MHC I (Figure 3A-C). Conversely, cells that 
expressed E7, but not E5, still had detectable MHC I (Figure 3D-F, H-J). Thus, it appears 
that expression of E7 is not responsible for down-regulation of MHC I.  
Although the lack of MHC I in the uppermost layers of the papillomas (Figures 2E, 3E) is 
consistent with the differentiated state of the cells, its absence in the basal (Figure 3B) and 
in the  immediate suprabasal (transit and lower spinous) layers (Figure 2E, boxed area 1) 
cannot be attributed to cell differentiation, as MHC I is present in these areas of normal 
mucosa (Figure 2A). Furthermore, MHC I is absent in similar areas of papillomas where 
E5 is not expressed (Figure 2D,E, boxed area 2).  
We conclude that E5 inhibits the expression of MHC I in BPV-induced papillomas, 
corroborating and validating our observations on down-regulation of MHC I by E5 in vitro. 
HPV-16 and other high risk HPV types induce cervical intraepithelial neoplasia (CIN), the 
precursor lesion of cervical cancer (zur Hausen, 2002). MHC I down-regulation has been 
observed in CIN, but E5 expression was not investigated (Bontkes et al., 1998). Given that 
HPV-16 E5 down-regulates MHC I (Ashrafi et al., 2004), and that HPV-16 E5 can be 
found in CIN samples (Chang et al., 2001), it can be speculated that E5 is responsible for 
MHC I down-regulation also in CIN.   
It remains to be seen whether the E5-induced down-regulation of MHC I leads to evasion 
of the host immune response, thus allowing the virus to establish the infection, and 
infection to persist. 
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Figure Legends 
Figure 1. Expression of E5 in BPV-4-induced papillomas. Representative papilloma 
sections stained with anti-E5 antiserum 274 (1:2000). A, papilloma 1803, showing E5 
expression in basal and suprabasal layers. B, papilloma 386, showing E5 expression 
in suprabasal layers. C, serial section of papilloma 386 incubated with secondary 
antibody only; D, normal buccal mucosa, showing no expression of E5. E, 
Autoradiograph of in vitro labelled S35-E5: lane 1, input E5 protein; lane 2, E5 
immunoprecipitated with antiserum 274; lane 3, E5 immunoprecipitated with 
antiserum 274 pre-absorbed with E5 C-terminus peptide. F, serial section of 
papilloma 386 incubated with pre-absorbed antiserum, showing loss of reactivity. 
Magnification: x40 (A), x20 (B,C,F) and x10 (D). 
 
Figure 2. Expression of MHC I in BPV-4-induced papillomas. Representative 
papilloma sections stained with anti-MHC I heavy chain mAb IL-A19 (1:200). A,  
section of normal buccal mucosa showing MHC I expression through most of the 
thickness of the epithelium. B, same as in A, at higher magnification, showing 
staining of MHC I on the cell surface. C, serial section of papilloma 386, stained with 
mAb IL-A19, showing lack of reactivity. D, section of papilloma 1804 stained with 
antiserum 274, showing E5 expression in suprabasal transit and lower spinous layers 
(boxed area 1) and in differentiated keratinocytes (black arrow). Boxed area 2 shows 
transit and lower spinous layers without E5 expression. E, serial section of papilloma 
1804, stained with mAb IL-A19, showing MHC I expression in cells lacking E5 
(boxed area 2), and lack of MHC I expression in cells expressing E5 (boxed area 1).  
Magnification: x10 (A,D,E) and x20 (B,C).  
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Figure 3. Expression of E5, E7, MHC I and Ki67 in BPV-4-induced papillomas. 
Representative papilloma sections stained with anti-E5 antiserum 274 (1:2000; panels 
A,D and H); with anti-bovine MHC I heavy chain monoclonal antibody IL-A88 
(1:200; panels B,E and I); anti-E7 antiserum 11547 (1:250; panels C,F and J), and 
with anti-Ki67 monoclonal antibody MIB-1 (1:200; panel G). A, papilloma 1803, 
showing expression of E5 in the basal layers. B, serial section of papilloma 1803, 
showing lack of expression of MHC I in cells expressing E5. C, serial section of 
papilloma 1803, showing lack of expression of E7 in the basal layers. D, papilloma 
1810, showing E5 expression in the differentiated keratinocytes but not in the basal 
cells. E, serial section of papilloma 1810, showing expression of MHC I in basal cells. 
F, serial section of papilloma 1810, showing expression of E7 in basal cells and co-
expression with E5 in differentiated keratinocytes. The boxed area in panel D and the 
corresponding areas in panels E and F are shown at higher magnification in panels H-
J respectively. G, serial section of papilloma 1810, showing expression of Ki67 in 
basal cells and in E5-expressing differentiated keratinocytes. Magnification: x40 (A-
C, H-J) and x20 (D-G).  
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